Generation Bio Co.
GBIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.81 | 0.05 | -0.15 | 0.12 |
| FCF Yield | -128.80% | -56.53% | -48.71% | -24.53% |
| EV / EBITDA | -1.18 | -1.03 | -1.59 | -0.91 |
| Quality | ||||
| ROIC | -64.10% | -40.40% | -38.03% | -25.49% |
| Gross Margin | 100.00% | -1,203.17% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.67 | 0.42 | 0.75 | 0.77 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -51.25% | 45.94% | -13.78% | -29.23% |
| Safety | ||||
| Net Debt / EBITDA | -0.23 | -0.24 | 0.08 | 2.57 |
| Interest Coverage | 0.00 | 0.00 | -31.08 | -2,382.02 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -75.62 | 93.74 | -47.10 | -162.93 |